Lurasidone Ingestions Reported to Texas Poison Centers

Background: Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia in 2010. There is limited information on potentially toxic events involving lurasidone outside of clinical investigations. Objective: This investigation describes potentially toxic lurasidone ingestions from a single data source. Methods: Cases were lurasidone ingestions reported to Texas poison centers during 2011 to 2013. The distribution was determined for selected characteristics. For management and outcome factors, analyses were limited to those cases without coingestants. Results: There were 140 lurasidone ingestions. Of the 72 cases with a reported dose, the mean dose was 536 mg (range = 20-4000 mg). The patient age was 5 years or less in 8.6% of the cases, 6 to 12 years in 2.1%, 13 to 19 years in 17.9%, and 20 years or more in 70.7%; 65.7% of the patients were female. The most commonly reported reason for the exposure was suspected attempted suicide, reported in 54.3% of the cases. No coingestants were reported in 55 (39.3%) of the cases. For these cases, the management site was 56.4% already at/en route to health care facility, 29.1% managed on site, and 10.9% referred to a health care facility. The medical outcome was known or suspected to not be serious in 65.5% of the cases. The most commonly reported clinical effects were drowsiness, agitation, and nausea. Conclusions: The majority of lurasidone ingestions reported to Texas poison centers involved adults and females. Over half were suspected attempted suicides and most involved coingestants. The majority of lurasidone ingestions without coingestants did not have serious outcomes.